Navigation Links
Cyprotex Introduces New Product Line Cloe(R) Select - a Portfolio of Bespoke ADME and PK Services
Date:4/2/2008

MACCLESFIELD, England, April 2 /PRNewswire-FirstCall/ -- Today, (2nd April 2008), Cyprotex announces that it is introducing a new product line, Cloe(R) Select. Cloe(R) Select is a portfolio of bespoke studies which can be customised to individual customer requirements. It complements the current range of Cloe(R) Screen assays to provide ADME (absorption, distribution, metabolism and excretion) and pharmacokinetic solutions from early discovery through to later stage development projects. As with Cloe(R) Screen, Cloe(R) Select meets the criteria set by the regulatory guidelines to provide constant confidence in the quality of the data.

The drug discovery and development process represents a number of pre-clinical phases which cover hit to lead, lead optimization and candidate selection. Cyprotex can now offer a fully integrated solution in the area of ADME and pharmacokinetics throughout this entire process. We have gained extensive knowledge in our field over the past 9 years, which is attributed to investing in high caliber committed scientists and by working with a large and diverse customer base.

Mr. Robert Atwater, Cyprotex's Chief Executive Officer, comments on the launch of this new product line. "Many of our customers rely on us for their ADME projects right from early screening projects through to IND submission. Building these relationships and ensuring that we can offer a flexible and broad range of screening options has been critical in the success of our business."

Cyprotex is a specialist provider of ADME data and pharmacokinetic predictive services. Our unique Cloe(R) Screen technology which couples robust protocols with state-of-the-art automation enables Cyprotex to offer an unrivalled combination of high quality, cost effective data with rapid turnaround. Introducing Cloe(R) Select ensures that Cyprotex can extend their offering to later stage more in-depth studies which require a more flexible approach. Cyprotex also has extensive expertise in physiologically based pharmacokinetic (PB-PK) modelling and quantitative structure activity relationship (QSAR) modelling techniques under its Cloe(R) Predict service. In combination, Cloe(R) Screen, Cloe(R) Select and Cloe(R) Predict offer an integrated solution for both experimental screening and prediction, fulfilling the needs of our broad and varied customer base.

For further information:

Cyprotex PLC,

Helen Gill PhD, Product Development Manager,

Tel: +44-1625-505-100,

h.gill@cyprotex.com.

http://www.cyprotex.com


'/>"/>
SOURCE Cyprotex Discovery Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
2. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
3. Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis
4. Small Bone Innovations Introduces New Distal Radius Plating System to Repair Complex Fractures
5. Advanced Instruments Introduces Worlds Fastest High Throughput Freezing Point Osmometer
6. Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology
7. Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features
8. Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments
9. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
10. WHO Introduces the Helminth Drug Initiative With Special Supplement in the Expert Opinion on Drug Discovery
11. H&V Introduces HVision Technology Platform to Accelerate Development of Breakthrough Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... Wausau, WI (PRWEB) , ... June 23, 2016 ... ... probiotic supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, ... supplements for over 35 years, is proud to add Target to its list ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
Breaking Biology Technology:
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
Breaking Biology News(10 mins):